Advances in Tumor Agnostic TRK Inhibitor Therapy and NTRK Fusion Testing

Watch this interactive, on-demand Webcast led by George D. Demetri, MD, and featuring an expert panel discussing best practices in testing for NTRK fusions in solid tumors, current evidence supporting the use of approved TRK inhibitors, and emerging topics, including TRK inhibitor resistance and second-generation agents.

George D. Demetri, MD
Program Director Alexander Drilon, MD Pashtoon M. Kasi, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 21, 2020 Expired: No longer available for credit

Introduction (2 mins)

Rationale for Targeting TRK Fusions in Solid Tumors and Implementing NTRK Testing in the Clinic (20 mins)

Clinical Data and Current Indications for TRK Inhibitors (19 mins)

TRK Inhibitor Resistance and Safety (19 mins)